Halozyme Therapeutics (HALO) Tops Q3 EPS by 5c; Offers FY23 Guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $71.15 +2.20%
EPS Growth %: +17.5%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +17.5%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.75, $0.05 better than the analyst estimate of $0.70. Revenue for the quarter came in at $216 million versus the consensus estimate of $218.7 million.
GUIDANCE:
Halozyme Therapeutics sees FY2023 EPS of $2.70-$2.80, versus the consensus of $2.65. Halozyme Therapeutics sees FY2023 revenue of $825-845 million, versus the consensus of $836 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
- FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
